INTRODUCTION
Histamine (2-(4-imidazolyl)-ethylamine) is a physiological amine that regulates cellular functions and triggers the inflammatory response. It interacts with receptors belonging to the G-protein coupled receptors (GPCRs) super-family. Based on sequence homology and functional similarities, GPCRs are grouped into six 
classes (1-2). H 4 receptor (H 4 R) belongs to class ''
A'' (a rhodopsin like family). To date, four histamine receptors activated by the same endogenous agonist, histamine are known (3) . H 4 R, cloned more than a decade ago on the basis of its high sequence homology with the H 3 receptor, is the most novel (4-8) (see Figure 1 and Table 1 ). H 4 R has been reported to be expressed on cells of the spleen, lungs, intestinal epithelium, stomach, salivary glands, and central nervous system, and on cancer cells (9) (10) (11) . However, H 4 R is mainly present in leukocytes and mast cells (5) (6) . This expression pattern implies that it plays a role in both immune and inflammatory responses. Indeed, a growing body of evidence indicates that H 4 R is involved in chemotaxis, allergies, inflammation, and autoimmune disorders that it acts as a release mediator in various types of immune cells including mast cells, eosinophils, monocyte-derived dendritic cells and T cells. Moreover, H 4 R is involved in the modulation of various interleukins, such as interleukin-B4 and interleukin-16 (12) (13) ; nominating it as a potential drug target for inflammatory diseases (13) (14) (15) . The physiological activity of H 4 R (and of GPCRs) is beyond the scope of this article but useful information can be found elsewhere (16) (17) .
Based on experiments using in vitro cell lines as well as animal models, hH 4 R antagonists show a reasonable therapeutic potential for the treatment of allergies, inflammation, asthma and colitis (18) (19) (20) (21) .
Although they have not been tested for efficacy in 458-478 (21) respectively. In parentheses we note the length of the helix. This figure was constructed using ClustalW2 for multiple sequence alignment run by EMBL-EBI website. © 1996-2016 common architecture of helices that cross the plasma membrane seven times, forming a bundle that has seven trans-membrane helices (7TMH) connected by intracellular and extracellular loops, with an extracellular N-terminal and an intracellular C-terminal (32) (see Figure 3 ). GPCRs derive their name from their ability to recruit and regulate the activity of intracellular heterotrimeric G-proteins. GPCRs are also known as seven-transmembrane domain receptors, 7TM receptors, heptahelical receptors, serpentine receptor, and G protein-linked receptors (GPLR). GPCR ligands make up a highly group of substances (e.g. ions, biogenic amines, nucleosides, lipids, peptides, proteins, and even light). The binding of such agonists to GPCRs results in signal transduction that induces a cascade of intracellular responses (9, (33) (34) . Ligand binding is followed by a conformational change that results in a decreased affinity of GPCRs to G-proteins, releasing them into the cytosol.
GPCRs are major contributors to the information flow into cells and, as such, are involved in a wide range of physiological processes and diseases, including those affecting the cardiovascular, nervous, endocrine, and immune systems. The cardinal involvement of GPCRs leads to their designation as drug targets in a multitude of therapeutic areas, to the effect that GPCRs are considered to be the largest group of drug targets to date. It has been estimated that GPCRs compose more than one-third of the targets for currently marketed drugs (35) (36) (37) (38) , and for 60-70 percent of the drugs in development (39) .
The structures of GPCRs should be elucidated in order to employ them for drug design and discovery, using the methods of "Structure Based Drug Design" (SBDD) (40) . However, the structural aspects of GPCRs have been a source of constant debate over the last two decades. The available high-resolution structural information on GPCRs proteins constitutes only about 2 percent of the data on this group, which is an impediment to understanding GPCR functioning mechanisms. Hence, the computational modeling of GPCRs has to face difficulties due to the lack of high-resolution information for most GPCRs.
Given that structure-based drug discovery is an efficient method for rationally designing novel drugs and improving the properties of old drugs, the scientific community has been striving for a long time to shed light on the elusive structure-function relationships of GPCRs, employing a variety of direct biophysical and indirect biochemical methods (41) . Direct experimental study of GPCR structures is currently too complicated because of their native membrane environment (42) , which poses limitations to the purification and crystallization processes. The first GPCR member protein, Bovine rhodopsin, was resolved in 2000 (43) , and since 2007, more than fifteen unique class "A" GPCRs have been crystallized in their active/inactive forms, including the avian β 1 adrenergic receptor (44) , the human β 2 adrenergic receptor(45), the A2A adenosine receptor (46) , the Histamine H1 receptor (47) , the Sphingosine 1-phosphate receptor (48) , the Dopamine The upper half of the matrix shows the sequence identity for the complete receptor sequence while the lower half shows the sequence identity of the trans-membrane domains. © 1996-2016 D3 receptor (49) , the CXCR4 chemokine receptor(50), the Muscarinic M2 receptor(51), the Muscarinic M3 receptor(52), the Kappa opioid receptor(53), the mu opioid receptor(54), the delta opioid receptor(55), the Protease-activator receptor 1 (56), the Neurotensin receptor (57), the human P2Y12 receptor (58) and the nociceptin/orphanin FQ (N/OFQ) peptidereceptor (59) . The GPCR-G protein complex structure has also been characterized by low-and high-resolution experimental methods (60) (61) (62) . Moreover, the crystal structures of all of the photo-activated intermediates of rhodopsin and some agonist-and antagonist-bound GPCRs were recently determined (63) (64) . This remarkable advancement in resolving GPCR structures is due to a combination of different techniques. The prospects for elucidating the structures of other GPCR proteins, however, are not great, and they await a major breakthrough (65) (66) . Structural information on GPCRs could be attained by the techniques of electron crystallography, electron paramagnetic resonance, UV absorbance and fluorescence spectroscopy, nuclear magnetic resonance (NMR) spectroscopy (67) (68) (69) and computer modeling. The predicted structures could also be validated by other experimental techniques such as the substituted cysteine accessibility method (SCAM) (70) (71) and site directed mutagenesis (72) (73) .
The location of the ligand-binding pocket is known for many GPCRs (74) (75) . For instance, peptides and proteins interact with the N-terminus and/ or the extracellular loop regions, while small organic molecules are known to bind within the transmembrane domain (TMD) (Figure 4 ). The binders to hH 4 R are small molecules and residues implicated in the binding of these ligands are mainly part of the TMD.
ab initio and de novo modeling
Two alternative computational approaches were used in order to build molecular models of GPCRs without using specific homologous template structures: ab initio (first-principles approaches) and de novo (knowledgebased approaches). ab initio structure prediction and de novo protein design are two problems at the forefront of research in the fields of structural biology and chemistry. The goal of an ab initio technique is to characterize the 3-D structure of a protein using only the amino acid sequence as input. Based on the independent folding concept introduced by Anfinsen (76) , ab initio modeling attempts to simulate the physical forces that drive protein folding, using energy functions such as molecular mechanics force fields as well as statistical functions. De novo protein design involves the production of novel protein sequences that adopt a desired fold. The experimentally resolved GPCRs are considered to be the prototypes of the main family of GPCRs, referred to as type A. The rhodopsin crystal structure has been used for a long time as a template for the homology modeling of the trans-membrane region of several GPCR subtypes. This paradigm is based on experimental evidence that suggests that part of the template conformation is similar to that of other GPCRs (38, 67, 69, (77) (78) . It is worth to assign that ab initio is very time consuming and perform well in modeling short peptides. However, for longer proteins, de novo is more efficient (91) .
Based on cryoelectron microscopy density maps, a cohort of models of helices were built, using the hydrophobicity properties of receptors and geometric parameters (79) . Similar methods were developed to predict the structures of GPCRs and ligand-binding sites, and relative binding affinities (80) . Although the GPCR conformational space is small compared to that of watersoluble proteins, it remains very complicated especially due to loops of variable lengths, non-conserved, non-canonical elements and unexpected structural diversity (45, 81) when compared to the rhodopsin crystal structure. The situation is further complicated by the presence of cavities that can accommodate water molecules and/ or different ligands. Another source of complexity is the possible influence of interacting GPCR subunits or other proteins of the signaling cascade. Thus, although de novo and ab initio methods may suggest reasonable TM arrangements of GPCRs, the accuracy of their predictions is limited by the experimental information available. As a result, homology modeling is considered a more reliable technique whenever applicable (82) . Moreover, while "ab initio/de novo" predictions for sequences shorter than ten residues have been quite reliable when using reasonable physical-chemical force fields that incorporate explicit water molecules etc. However, they increase the computational complexity and are thus not applicable to large proteins. This would suggest that physical-based GPCR modeling should be abandoned in favor of a non-physical method, such as homology modeling. However, due to insertions and deletions, the loop regions in GPCRs exhibit variable length and low sequence identities (below 30 percent) (83) . Hence, it is not reasonable to initiate homology modeling based on the loops of known GPCR structures. De novo/ab initio computational approaches using either coarse-grained backbone dihedral sampling (84) or Monte Carlo (MC) simulations in a temperature annealing protocol combined with a scaled collective variables (SCV) technique (85) have been shown to accurately predict loop regions of GPCRs with decreasing performance at increasing loop lengths. The prediction of longer and interacting motifs is still a very challenging task (86) . The failure of current "de novo/ab initio" approaches to predict long peptides stem from the difficulty of carrying out sufficiently complete searches of their conformational spaces, as well as from the inaccuracy of current force fields (87).
Homology (comparative) modeling
Due to the lack of experimentally determined 3-D structures of most GPCRs, one could hope to gain some information from approximations based on molecular models. While "de novo/ab initio" modeling is not yet practical for any protein (88) (89) (90) , "homology" modeling is an established method (89, 91) . Unlike the "de novo/ab initio" methodologies, homology based modeling techniques rely on the existence of solved structures, which serve as design templates (92) . Indeed, many GPCRs have been modeled recently, based on the crystal structure of different, solved GPCRs, by using their backbone coordinates and adding the appropriate side chains for each sequence (93) (94) (95) (96) (97) . Such homology modeling of GPCRs has been aided mainly by experimental information from point mutations and other experimental data sources (45, (98) (99) .
In homology modeling, the modeled protein retains some of the features of the selected template. The length of helices in the modeled TMD remains similar to those of the template receptor while the loops are generally not included in the template construction, except in rare cases when loop lengths and compositions are similar to those of the template. Other approaches for constructing models of GPCRs suggest that GPCRs could differ in their structure from resolved receptors even though their general features are similar (100-101). However, there are few indications to justify such deviations from the template structure, when constructing models for other GPCRs. A review by Baker and Sali (102) has shown that a homology model for a protein of medium size or larger with a sequence identity of less than thirty percent to the template crystal structure is unreliable. The average sequence identity of the trans-membrane helices (TMHs) of hGPCRs to experimentally resolved GPCRs generally rests outside the regimen boundaries of traditional homology modeling (38) . Others in the modeling community think that while this "rule" is correct for globular proteins, it is doubtful whether it should be extended to membrane proteins. Moreover, this rule does not specify how identity should be distributed along a sequence. As much as the GPCR super-family is united by an overall structural topology and an ability to recruit and regulate the activity of G proteins, sequence identity between superfamily members, despite the conserved transmembrane cores, is too low. Significant sequence conservation is found, however, within several subfamilies of GPCRs. The family of rhodopsin-like GPCRs is so far the largest (more than 85 percent of GPCRs) and is characterized by the presence of some 35 (out of ~190) highly conserved residue positions in the TMD, which may be crucial for folding and/or which may be involved in binding and/or in activation (103) . By sequence analysis of the TMD of 302 GPCRs, Palczewski and colleagues (104) concluded that it is reasonable to speculate that the overall fold of these receptors is highly conserved. One implication of this study is that it is reasonable to use the overall structures of available reference receptors to model the TMD of other GPCRs using homology modelling.
Another obstacle to the modelling of GPCRs is the conformational change that may accompany with activation. In contrast to the inactive state of GPCRs, a relatively small number of active state structures are available to date-e.g. the Neurotensin Receptor 1, the human β 2 -Adrenergic Receptor, the adenosine A2A receptor and the human P2Y12 receptor (57) (58) (105) (106) (107) (108) . While these structures provide some information, they are too few to warrant generalizations about the active state and in most cases, insufficient to justify homology modeling solely on active state structures. Given this lack of experimental structural information, several investigators have applied computational strategies to predict activated models of GPCRs (84, (109) (110) (111) (112) (113) (114) . Although the rhodopsinactivated models generated to date appear to satisfy most of the experimental data known for GPCRs, novel predictions deriving from their analyses still await experimental validation. Moreover, it remains to be determined whether or not all GPCRs share the same activated forms.
A study by Rayan (38) examined the extent to which the structures of a five resolved GPCRs are useful as templates for constructing models of other GPCRs. A quantitative measure of conservation in the GPCR family was helpful for determining exactly which parts of the receptors could be used as templates for such comparative modeling, and which should be optimized. The study identified which parts of the structure of the reference receptor may be used as templates, and suggested the construction of the remaining parts by other methods that allow deviations from the crystal structure of the template.
3-D STRUCTURE MODELS OF THE HUMAN H 4 RECEPTOR
The H 4 receptor has been modeled by several groups based on the resolved structures of bovine rhodopsin, the β 2 -adrenergic receptor and the H 1 receptor. Table 2 summarizes the published H 4 R models.
Rhodopsin-based homology modeling era: 2000 -2007
The 3-D structure of the hH 4 R is considered by investigators to be key to understanding the role of histamine binding to the receptor and to designing novel ligands. After the hH 4 are not involved in histamine binding. Taken together, these data indicate that, although histamine seems to bind to the hH 4 R in a fashion similar to that predicted for the other histamine receptor subtypes, there are also important differences that can probably be exploited for the discovery of novel hH 4 R selective compounds.
In 2008, while developing homology models of the hH 4 R, Kiss and coworkers (116) confirmed that histamine has two major anchoring points at the hH 4 Figure 2) , can explain the observed differences in binding to the H 4 R mutants. These studies provide a molecular understanding of the action of a variety of H 4 R ligands. Using mutational analysis, Jongejan et al. (120, 121) found that the glutamic acid residue Glu182 5.4.6 is the source of the increased affinity of histamine observed for both the H 3 R and H 4 R. In the resultant H 4 R model, TM3 is repositioned relative to the core architecture of rhodospin, due to the presence of two unique glycine residues in TM2 of the rhodopsin structure. These result in a slight bend of TM3 at position 99, toward TM5. Asp94 3.3.2 , the major site of interaction for ligands containing a protonated moiety, thereby becomes situated in even closer proximity to Glu182 5.4.6 .
To differentiate between the active and inactive forms of the receptor, Jojart (122) carried out molecular dynamics (MD) simulations in an explicit membrane (POPC/TIP3P) and water molecule environment, using the homology model of the hH 4 R. The MD simulations were conducted on the receptor alone, in complex with its endogenous activator histamine and with the selective hH 4 R antagonist JNJ7777120. These models were built by using the crystal structure of bovine rhodopsin as a template (114) . The complex structures were obtained after docking experiments and subsequent optimization. During the simulation of the histamine-hH 4 R complex, considerable changes occurred in the hH 4 R structure, as well as in the interaction pattern of histamine at the binding site. These changes were in agreement with experimental data published on GPCR activation. In particular, the intracellular side of TM6 moved significantly away from TM3 and TM7. Histamine's ethylamine 4 R activation, because its mutation to non H-bond donor residues lowers hH 4 R activation. The MD simulations of the native hH 4 R and the JNJ7777120-hH 4 R complex suggest that these models represent an inactive conformation of hH 4 R. MD simulation in the presence of JNJ7777120 resulted in the movement of the intracellular side of TM6 toward TM3, opposite to the outward movement that is more characteristic of its activated state. This modeling strategy provided an ensemble of 3-D structures for both active and inactive receptors. As the authors suggested, this ensemble is potentially useful for structure-based drug design (122).
The differences in binding mode between the agonist and antagonist were studied as well, based on the crystal structure of bovine rhodopsin and of distinct known H 4 receptor ligands (123) (histamine, OUP-16 (the first reported H 4 agonist with a considerable selectivity over H 3 R (124)) and JNJ7777120 (the first reported selective H 4 antagonist (125))). Experiments were conducted by Kiss et al. (123) to determine whether these hH 4 R models can pick up "actives from haystack." The impact of receptor conformation and the effects of different sets of random decoys, docking methods (FlexX, FlexX-Pharm) and scoring functions (FlexX-Score, D-Score, PMF-Score, G-Score, ChemScore) were investigated. It was found that two agonists (histamine and OUP-16) (Figure 2 , whereas JNJ7777120 interacts with Asp94 3.3.2 and Glu182 5.4.6 only. These results suggest a role for Thr323 6.5.5 in agonist binding, and presumably in receptor activation. Also, the type of the ligand that is utilized in modeling and model refinement can significantly influence efficacy in virtual screening. Six initial hH 4 R models were built by the MODELLER program. In accordance with the sequence alignment, the model contained a disulfide-bond between residues Cys87 3.2. 5 and Cys164 (in extracellular loop 2). Several tests were performed to check the quality of the more suitable hH 4 R model by assessing the Ramachandran plots and packing quality. The overall quality of the model and the template were quite similar. Tests using HARMONY (126) indicated that the model and the template possess quite the same overall quality (40).
Human β 2 -adrenergic receptor based homology modeling era: 2007 -present
The crystallization of human β 2 -adrenergic receptor (hβ 2 AR) has opened a new focus of study in order to detect variations in binding mode in response to species variations. The natural variation in H 4 R sequence enabled Lim and his colleagues (127) to identify amino acids involved in the binding of H 4 R agonists. After identification of a domain between the top of TM4 and the top of TM5 as being responsible for the differences in agonist affinity between human and mouse H 4 receptors, detailed site-directed mutagenesis studies were performed. These studies identified Phe169 in the second extracellular loop as the single amino acid responsible for the differences in agonist affinity between the human and mouse H 4 Rs. Phe169 is part of a Phe-Phe motif that exists in the β 2 AR and was structurally determined by crystallographic methods (45) . These results point to an important role of the second extracellular loop in the agonist binding to the H 4 R and provide a molecular explanation for the species difference between human and mouse H 4 Rs.
The hH 4 R was modeled based on the crystal structure of β 2 -adrenergic receptor (Protein Data Bank code 2RH1), which lacks the N-terminal tail and contains a T 4 ligase structure in the third intracellular loop (IL3) (45) . The latter was removed in the model template. A large part of IL3 of the H 4 R was removed to fit the length of the IL3 of the template. Alignment constraints were applied to avoid gaps in TM domains between Thr146 (in extracellular loop 2) and Gly128 4.5.8 , Leu167
(in extracellular loop 2) and Pro149 4.5.8 of β 2 -adrenergic receptor and H 4 R, respectively. In extracellular loop 2 (EL2), constraints were put between Cys191 and Cys164, Phe193, and Phe168, Tyr174 and Ser156 of the β 2 AR and H 4 R respectively. This alignment was used to run homology modeling and resulted in models with a preserved disulfide bridge.
Another study by Deml et al. (128) aimed to explore the value of dual H 1 R/H 4 R antagonists as anti-allergy drugs and to address the question of whether H 1 R ligands bind to hH 4 R based on the crystal structure of hβ 2 AR. In an acute murine asthma model, the H 1 R antagonist mepyramine ( Figure 5 ) and the H 4 R antagonist JNJ7777120 ( Figure 6 ) exhibited synergistic inhibitory effects on eosinophil accumulation in bronchoalveolar lavage fluid. As assessed in competition binding experiments, eighteen H 1 R antagonists and twenty-two H 1 R agonists showed a lower affinity to hH 4 R than to hH 1 R. Most compounds were neutral antagonists or inverse agonists. Twelve phenylhistamine-type hH 1 R partial agonists were found to be hH 4 R partial agonists. Four histaprodifen-type hH 1 R partial agonists were hH 4 R inverse agonists. Dimeric histaprodifen proved to be a more efficacious hH 4 R inverse agonist than the reference compound thioperamide. Suprahistaprodifen was the only histaprodifen acting as a hH 4 R partial agonist. Suprahistaprodifen docked in the binding pocket of inactive Specific to the acute asthma model, the interactions of H 1 R and H 4 R antagonists and agonists indicate that the development of dual H 1 R/H 4 R antagonists is a worthwhile and technically feasible goal for the treatment of type-I allergic reactions. To generate an inactive hH 4 R model, the sequence of hH 4 R was aligned with hβ 2 AR. Based on this alignment, the homology model of the inactive hH 4 R was generated using the crystal structure of the hβ 2 AR (Protein Data Bank, code 2rh1). Loops with lengths that differed from those of the hβ 2 AR were modeled using the Loop Search module of SYBYL (Tripos, St. Louis, MO). Thereafter, the minimized receptor was manually placed in a membrane bilayer model, and suprahistaprodifen was positioned manually into the binding pocket in two different orientations. To refine the hH 4 R homology model, representing the inactive state, distance-restrained molecular dynamic simulations, using the constraints of the inactive conformation, were also performed, with explicit simulation of water molecules (114) . The active model of the hH 4 R was generated with a distance-restrained MD simulation, based on the constraints for the active conformation. In addition, distance restraints for the hydrogen bonds of the transmembrane helices were applied. All simulations were carried out as described for H 1 R by Strasser and colleagues (129) , where dimeric histaprodifen was docked in the binding pocket of the guinea pig H 1 R (gpH 1 R). Hydrogen bonds and electrostatic interactions were then detected between dimeric histaprodifen and Asp116, Ser120, Lys187, and Glu190. The authors assessed the influence of the Tyr72 2.6.0 Asn mutation in hH 4 R upon interaction with suprahistaprodifen and came to the conclusion that the exchange of Asn 2.6.1 against Tyr 2.6.1 in hH 4 R, compared to hH 1 R, had little impact on the interaction with suprahistaprodifen.
In 2009, Igel and coworkers (27) developed a homology model of the hH 4 R based on the crystal structures of the hβ 2 AR. Their work focused on the binding site of the cyanoguanidines. One compound in the cyanoguanidine family (see the cyanoguanidine derivative in Figure 6 ) was manually docked in an energetically favorable conformation, while taking into consideration results from in vitro mutagenesis and modeling approaches. The binding site of the compound mentioned above, consisting of twenty amino acids with side chains < 3Å distant from the ligand, is located between TM2 and TM7, and the imidazole moiety was docked at this site. In this binding mode, Glu182 5.4.6 is presumed to be protonated and to serve as a hydrogen bond donor for the π nitrogen. The τ nitrogen forms another H-bond with the side-chain oxygen of Thr178. However, a similar bi-dentate interaction is possible with the couple Ser179 Ala mutations lead to only a three-to fourfold reduction of histamine affinity and potency. Thus, no definitive conclusion about the presence and the partner of a second hydrogen bond can be drawn. In this mode, the cyanoguanidine moiety is stacked with the phenyl ring of Phe344 7.3.9 and forms two charge-assisted hydrogen bonds with the carboxylate oxygens of Asp94 3.3.2 (with distances of 2.0.-2.1. Å), an amino acid proven to be essential for histamine binding by in vitro mutagenesis. This arrangement allows the arylthioalkyl substituent of the compound, like the isopropyl group of carazolol in the crystal structure of the β 2 -adrenoceptor, to point outward. The cyano-group in the Z configuration forms two additional charge-assisted hydrogen bonds with the guanidine moiety of Arg341, which is also involved in a salt bridge with Glu165 (in extracellular loop 2). This arginine is species-specific (it would be serine instead in the rat and mouse receptor) and is replaced by a glutamate in the hH 3 R. This suggests that interactions with Arg341 7.3.6 may contribute to the hH 4 R subtype and the species selectivity of the cyanoguanidines. The binding mode is more likely, since a nearly perpendicular conformation of the imidazolyl ring with respect to an alkyl chain is energetically favorable and present in the crystal structure of histamine monohydrobromide as well.
In 2011, a team headed by Chris de Graaf and Rob Leurs (130) reported the use of a β 2 -adrenergic based homology model of hH 4 R to identify residues that might play an important role in ligand binding and to identify the molecular determinants of H 3 R/H 4 R selectivity. They stated that the hH 4 R homology model based on the H 1 R crystal structure is very similar to the hH 4 R model which was constructed on the basis of the β 2 -adrenergic crystal structure. According to this study, the ligand clobenpropit (see Figure 7) can adopt two different binding modes for the hH 4 R, while adding a cyclohexyl group to the clobenpropit isothiourea moiety allows the new ligand (VUF5228) to adopt only one binding mode.
Aiming to design an anti-inflammatory drug candidate, Levita and colleagues (131) , generated two models of the hH 4 R, using the human adenosine A2A receptor (PDB code: 3em1) and the β 2 -adrenergic receptor crystal structure (PDB code: 2rh1) as templates. SWISS-PROT (http://swissmodel.expasy.org) and MODELLER 9v7 (http://salilab.org/modeller) were applied to complete the missing parts of the models. The researchers reported that the hH 4 R 3-D model produced by MODELLER, using 2rh1 as a template, was the best model, based on DOPE value and Ramachandran plot analysis. Histamine ligand was docked by AutoDock 4.0. on the receptor model and placed at its predicted binding site, which consists mainly of six amino acid residues: Asp94 A team headed by Suresh (132) aimed to develop a homology model that could be used for structure-based virtual screening and could also disclose a novel scaffold for designing potent and selective hH 4 R antagonists. They used I-TASSER, a web-based structure prediction server, to construct the 3-D structure of hH 4 R, using the human β 2 -adrenergic GPCR (PDB ID: 2rh1A) as a template. The generated models were validated for virtual screening application by PROCHECK (133) and ERRAT (134) . The ligand fit module of Discovery Studio (version 2.0., Accelrys, Inc., San Diego, CA, USA) was used to dock 392 chemicals retrieved from PubChemone hundred and fifty analogues of JNJ7777120, 49 thioperamide analogues and 193 Vuf6002 analogues. The successful docked poses were evaluated using a set of scoring functions (LigScore1, LigScore2, PLP1, PLP2 and PMF), as implemented in the Discovery Studio software. Six substances with high docking scores were chosen as potential leads for hH 4 R antagonists.
human H 1 receptor and others based homology modeling era: 2011 -present
In 2011, the crystal structure of human histamine H 1 R (47) was released to the Protein Data Bank (PDB entry: 3RZE, resolution 3.1.0 Å), and its discovery significantly facilitated the structure-based drug discovery of histamine receptors. Using Discovery Studio (version 2.5.), Feng and colleagues (135) constructed a homology model of the hH 4 R, using the crystal structure of H 1 R as a template. Once the 3-D model was generated, energy minimization was performed. The docking program CDocker and Discovery Studio's Catalyst Score were used to construct receptor-ligand complexes. The binding pocket was defined by aligning the center of the binding site with the center of the ligand in the H 1 R crystal structure. Using this model, the researchers studied the binding mode of the hH 4 R for eight ligands, which included six agonists (histamine, imetit, clobenpropit, OUT16, 4-methylhistamine, clozapine) and two antagonists (JNJ7777120, VUF6002). They found that there are two binding modes, but all of the ligands shared a preferred one, where the protonated part tightly interacted with Asp94 3.3.2 , while the imidazole-NH of the ligand interacted with Glu182 5.4.6 . As well, they determined that Glu165 (in extracellular loop 2) and Thr323 6.5.5 are two important residues involved in the binding pocket of the hH 4 R and contribute to its selectivity.
Early in 2014, researchers from Gedeon Richter corporate (136) published a methodology for screening fragments and detecting hits for that bind to the hH 4 R and the dopamine D 3 receptor. They concluded that X-ray structures, homology-based models and structural ensembles, were all suitable for the docking-based virtual screening of fragments against both receptors. The results obtained from the various models complemented each other, with little overlap among their hit sets. The authors identified some flexibility within the hH 4 Due to such flexibility, we think that using an ensemble of structures for docking and virtual screening purposes would be the best way to increase hit rates.
De Graaf and Leurs demonstrated (137) how a combination of ligand structure-activity relationships, quantum mechanics-based ligand conformation analysis and structural modeling could help to elucidate the binding mode of 2-aminopyrimidine derivatives in the hH 4 R binding pocket, as well as the molecular determinants of hH 4 R ligand binding. The 3-D structural model of the hH 4 R was built based on the H 1 R crystal structure. Their studies revealed that ligands bind hH 4 R with a high binding affinity and efficacy by forming ionic interactions with Glu182 5.4.6 and by optimizing hydrophobic interactions with the proteinbinding pocket, while taking up an energetically favorable conformation. In 2013, Schultes et al. (138) described how a combination of in silico and experimental approaches could be utilized to map ligand-protein interactions. Two models for the native hH 4 R were built: the first one was based on the recently resolved H 1 receptor crystal structure, while the second model was based on the β 2 -adrenergic receptor crystal structure. The models had very similar transmembrane domain tertiary structures and overall showed the same ligand-receptor interactions. Schultes et al. reported that the models showed comparable efficiency in retrospective virtual screening studies. They focused on the elucidation of the binding modes of two varied selective hH 4 R ligand classes: indocarboxamides and 2-aminopyrimidines (see Figure 8) . Recently, Engelhardt et al. described (139) how comprehensive structure-activity relationship analysis, in combination with homology modeling, enabled them to establish a detailed binding model of bispyrimidine (see Figure 9 ) in the hH 4 R © 1996-2016 and to identify the subunit replacing the N-methylpiperazine moiety that exists in most hH 4 R ligands. The PLANT docking algorithm (140) , without any constraints, was used to verify the compound's binding modes.
Recently, a team headed by Guccione and Rayan described (141) a combined ligand-based and structure-based approach for indexing chemicals for their hH 4 R antagonism. The strategy was composed of two subsequent stages. In the first stage, two ligand-based chemoinformatics techniques, the Intelligent Learning Engine (ILE) (142) and the Iterative Stochastic Elimination approach (ISE) (143) (144) , were used to screen a large chemical database (145) and select a set of chemicals highly indexed as hH 4 R antagonist candidates. Next, different hH 4 R structural homology models were constructed, and their capability for differentiating between active and non-active hH 4 R antagonists was checked by docking a validation set of active ligands. To rank the ligands and the docked poses, in addition to the AutoDock4 energy (electrostatic term), the filter of the ability to interact with Asp94 3.3.2 and Glu182 5.4.6 through hydrogen bonding/electrostatic interaction, was taken into account. The authors came to the conclusion that the model constructed by extensive molecular dynamics simulation, conducted in a DOPC lipid membrane and with a docked ligand inside, is the most efficient model for docking purposes and virtual screening. As well, ligand-based chemoinformatics techniques, in sequential combination with molecular modeling techniques, are claimed to have the potential to improve the success rate for discovering new biologically active compounds and to improve enrichment factors in a synergistic manner.
Ligand-based prediction (without using homology models)
In an attempt to study how we could transfer ligand information into a homology-based receptor model, new methods have been developed. A study by Tanrikulu et al (146) presented a computer-assisted method for the generation of a pseudo-receptor model for a putative ligand binding site based on a threedimensional alignment of known histamine H 4 receptor ligands. Following alignment, hydrogen bond donors/ acceptors were projected outwards with the appropriate binding distances and geometries to provide pseudoreceptor atoms. Each pseudo-atom was then weighted according to the number of atoms that generated it in each ligand as well as the number of ligands that created it and a correlation vector was obtained. The resulting model was used for the virtual screening of a large collection of commercially available compounds with two bioactive chemotypes retrieved.
The pseudo-receptor model was also used to find the putative ligand binding pocket within the transmembrane domain of the receptor together with a homology model based on the β 2 -adrenergic receptor template. The homology model was simulated using molecular dynamics, with an explicitly simulated environment of water and lipids. For each frame of a molecular dynamics simulation of a homology-based H 4 receptor model, potential ligand binding pockets were automatically extracted and their compatibility with the pseudoreceptor was used as a selection criterion. The This new pseudoreceptor approach has demonstrated its suitability for both the structure-based prioritization of protein receptor models, and ligand-based virtual screening with the aim of performing scaffold hopping. An automated pseudoreceptor construction algorithm (PRPS, pseudoreceptor point similarity) was developed and used to transfer ligand information into a homology-based receptor model for the H 4 R antagonist binding pocket.
The MembStruk method for predicting the 3D structure of several GPCRs including the H 4 R, without utilizing homology modeling techniques was developed recently (147) . Predicted structures were validated by using the HierDock procedure (148) or MSCDock (149) (150) to predict their characteristics (sites, configurations, and binding energies to known high affinity ligands (agonists and antagonists). Predictions did not depend on experimental data, but rather were compared to it. The predicted structure for the ligand-GPCR complex was then used to predict which mutations would dramatically decrease or increase binding. HierDock/ MSCDock was thus applied to successfully predict the binding site structures and binding energies of some ligands including those that bind to H 4 R.
To explore the possible structure-function relationships of the hH 4 R, as a receptor species with high constitutive activity, molecular modeling of an active hH 4 R state in complex with Gα i2 -CTs was performed (151) . This study was based on a model of the putative active state of the hH 4 R, on the inactive state model (27) and on recent data on the crystal structure of opsin in complex with a C-terminal fragment of transducin (Protein Data Bank, 3DQB) (152) . The alignment of the active hH 4 R model with the inactive hβ 2 AR structure showed that the main difference consists of an outward tilt of TM6, resulting in a distance of approximately 6.5.Å at the intracellular end (position of Arg297 6.2.9 ) (151). The bottom of TM5 and TM7 deviate by approximately 2 and 2.5.Å, respectively. The segments TM2-TM4 were found to be rather well aligned (the rms fit of the backbone atoms was approximately 1.2.Å). At the intracellular end of TM5, two residues of the hH 4 R, Asp205 and His206, were found to be nearly unique among all biogenic amine GPCRs. Asp205 forms a salt bridge with Arg299 6.3.1 , which may be regarded as an ionic lock stabilizing the active receptor state. In summary, 14 contacts may be formed with the participation of hH 4 R residues from TM2, TM3, EL2, EL3, TM6, and the C-terminal helix 8. Interactions of the Gα i2 C terminus with the receptor seem to enforce the proper fold of the last four Gα i2 residues.
In 2011, Fernandes and his colleagues, (153) published their work reporting the utility of QSAR and molecular modeling for predicting indole and benzimidazole derivatives as hH 4 R antagonists. Thirty compounds were used as a training set, and for characterization of the molecular structure, a total of 63 descriptors of diverse nature (structural, lipophilic, electronic, topologic, steric and thermodynamic) were calculated. Four out of five compounds in the external test set were correctly classified, and the proposed model yielded a success rate of 80 percent.
CONCLUDING REMARKS
In silico methodologies and techniques for modeling hH 4 R, together with emerging experimental data, have led various research groups to construct high quality models for this receptor, which have been utilized in studies of the structure activity relationships of ligands, the elucidation of binding modes, and the virtual screening of chemicals' databases. Most reported models have a sufficient level of accuracy to enable effective discrimination between binders and nonbinders. However, these models were not tested on their capabilities for ranking the affinities of a series of analogues in order to exploit them for lead-optimization purposes. We believe that flexible docking, simultaneously employing more than one three-dimensional model of the receptor, could improve the docking results. As well, a combination of ligand-based and structure-based modeling could yield better results in virtual screening experiments.
One of the underlying difficulties in integrating the various models produced emanates from the lack of an organized depository for modeled proteins. This requires laboratories interested in comparative studies to individually collect models. We suggest the collection of all hH 4 R models for a comparative study aimed at optimizing binding prediction. Using existing docking tools, agonists and antagonists of known binding affinities can be docked to the various models and the hH 4 R models can be ranked according to the correlations between the predicted and experimental binding affinities of docked ligands.
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